× How Are New Vaccines Prioritized in Low-Income Countries? A Case Study of Human Papilloma Virus Vaccine and Pneumococcal Conjugate Vaccine in Uganda

× Trade Agreements and Direct-to-Consumer Advertising of Pharmaceuticals

× Shaping Policy Change in Population Health: Policy Entrepreneurs, Ideas, and Institutions

× The Global Health Policies of the EU and its Member States: A Common Vision?

× Reaching Outside the Comfort Zone: Realising the FCTC’s Potential for Public Health Governance and Regulation in the European Union Comment on “The Legal Strength of International Health Instruments – What It Brings to Global Health Governance?”

× Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries 

× The Economic Impact of Clinical Research in an Italian Public Hospital: The Malignant Pleural Mesothelioma Case Study

× Disturbing the Doxa of Patient Safety Comment on “False Dawns and New Horizons in Patient Safety Research and Practice”

× A Crisis of Humanitarianism: Refugees at the Gates of Europe

× Nurturing Societal Values in and Through Health Innovations Comment on “What Health System Challenges Should Responsible Innovation in Health Address?” 

× A Scoping Review of Populist Radical Right Parties’ Influence on Welfare Policy and its Implications for Population Health in Europe

× Around the Tables – Contextual Factors in Healthcare Coverage Decisions Across Western Europe

× Is a Decentralised Health Policy Associated With Better Self-rated Health and Health Services Evaluation? A Comparative Study of European Countries

× It’s Time to Finally Kill the Zombies Comment on “Universal Pharmacare in Canada”

× The Challenges of Canadian Pharmacare Are More Complicated Than Acknowledged Comment on “Pharmacare in Canada”

× Understanding the Battle for Universal Pharmacare in Canada Comment on “Universal Pharmacare in Canada”

× Getting the Problem Definition Right: The Radical Right, Populism, Nativism and Public Health Comment on “A Scoping Review of Populist Radical Right Parties’ Influence on Welfare Policy and its Implications for Population Health in Europe”

× Introducing Voluntary Assisted Dying: Staff Perspectives in an Acute Hospital

× Policy Challenges Facing the Scale Up of Integrated Community Case Management (iCCM) in Uganda

× Impact of Non-pharmaceutical Interventions on the Control of COVID-19 in Iran: A Mathematical Modeling Study

× Policy Instruments for Health Promotion: A Comparison of WHO Policy Guidance for Tobacco, Alcohol, Nutrition and Physical Activity

× The Effects of Cost Containment and Price Policies on Pharmaceutical Expenditure in South Korea

× Usefulness of Home Screening for Promoting Awareness of Impaired Glycemic Status and Utilization of Primary Care in a Low Socio-Economic Setting: A Follow-Up Study in Reunion Island

× The Economic Value of Non-professional Care: A Europe-Wide Analysis

× Epidemics, Lockdown Measures and Vulnerable Populations: A Mixed-Methods Systematic Review of the Evidence of Impacts on Mother and Child Health in Low-and Lower-Middle-Income Countries

× Neurotrauma Surveillance in National Registries of Low- and Middle-Income Countries: A Scoping Review and Comparative Analysis of Data Dictionaries

× Donations Made and Received: A Study of Disclosure Practices of Pharmaceutical Companies and Patient Groups in Canada

× Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe

× More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry’s Role in Widening the Access Gap

× Neurotrauma Registries in Low- and Middle-Income Countries for Building Organized Neurotrauma Care: The LATINO Registry Experience Comment on “Neurotrauma Surveillance in National Registries of Low- and Middle-Income Countries: A Scoping Review and Comparative Analysis of Data Dictionaries”

× Global Neurotrauma Surveillance: Are National Databases Overrated? Comment on “Neurotrauma Surveillance in National Registries of Low- and Middle-Income Countries: A Scoping Review and Comparative Analysis of Data Dictionaries”

× Towards Improved Organizational Governance of Neurotrauma Surveillance Comment on “Neurotrauma Surveillance in National Registries of Low- and Middle-Income Countries: A Scoping Review and Comparative Analysis of Data Dictionaries”

× The Role of Registries in Neurotrauma Research: Translating Data Into Health Policy That Enhances Patient Care Comment on “Neurotrauma Surveillance in National Registries of Low- and Middle-Income Countries: A Scoping Review and Comparative Analysis of Data Dictionaries”

× National Trauma Registries in LMICs: Long-Overdue Priority Comment on “Neurotrauma Surveillance in National Registries of Low- and Middle-Income Countries: A Scoping Review and Comparative Analysis of Data Dictionaries”

× National Neurotrauma Registry Data in Low- and Middle-Income Countries – Current Status and Future Requirements Comment on “Neurotrauma Surveillance in National Registries of Low- and Middle-Income Countries: A Scoping Review and Comparative Analysis of Data Dictionaries”

× Commercializing Personal Health Information: A Critical Qualitative Content Analysis of Documents Describing Proprietary Primary Care Databases in Canada

× Impact of the Regulatory Framework on Medical Device Software Manufacturers: Are the Guidance Documents Supporting the Practical Implementation? Comment on “Clinical Decision Support and New Regulatory Frameworks for Medical Devices: Are We Ready for It? – A Viewpoint Paper”

× Factors Associated With In-Hospital Death Among Pneumonia Patients in US Hospitals From 2016~2019

× Characteristics and Distribution of Scholarship Donations From Pharmaceutical Companies to Japanese Healthcare Institutions in 2017: A Cross-sectional Analysis

× Health System Considerations for Community-Based Implementation of Automated Respiratory Counters to Identify Childhood Pneumonia in 5 Regions of Ethiopia: A Qualitative Study

× Phase IV Drug Trials With a Canadian Site: A Comparison of Industry-Funded and Non-Industry-Funded Trials